Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels.
about
A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, IndiaImmunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccinePerformance of rotavirus vaccines in developed and developing countriesImmunology of Gut Mucosal VaccinesPediatric small intestine bacterial overgrowth in low-income countries.Assessment of environmental enteropathy in the MAL-ED cohort study: theoretical and analytic framework.The hows and whys of constructing a native recombinant cholera vaccine.Maximizing protection from use of oral cholera vaccines in developing country settings: an immunological review of oral cholera vaccines.Preliminary assessment of the safety and immunogenicity of a new CTXPhi-negative, hemagglutinin/protease-defective El Tor strain as a cholera vaccine candidate.Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama.Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccinationAttenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O.Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines.A Single Dose of Oral BCG Moreau Fails to Boost Systemic IFN-γ Responses to Tuberculin in Children in the Rural Tropics: Evidence for a Barrier to Mucosal Immunization.Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.Effectiveness of rotavirus vaccine in preventing severe gastroenteritis in young children according to socioeconomic status.Age-dependent association among Helicobacter pylori infection, serum pepsinogen levels and immune response of children to live oral cholera vaccine CVD 103-HgRSafety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks.Safety and immunogenicity assessment of an oral cholera vaccine through phase I clinical trial in Korea.Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit.A randomized, placebo-controlled, double-blind Phase 2 trial comparing the reactogenicity and immunogenicity of a single ≥2x108 colony forming units [cfu] standard-dose versus a ≥2x109 cfu high-dose of CVD 103-HgR live attenuated oral cholera vaccin
P2860
Q21144301-27E8E433-0175-4F4F-BD25-76B5FBAD8977Q21245322-8B70B853-E2F7-4183-BBCE-519C5A513D52Q24600612-4994522C-EF17-4A07-A528-CE3CBABDEB97Q28972559-886D1EF3-7A27-4C26-BD7F-458CF3E97066Q30301148-52C1C825-FDA4-4590-BB9E-D2BFAE0639FFQ30303118-1693EC4E-77D6-494F-B2C7-CBD05E19FA94Q33560076-8D610872-68BE-435F-9868-0E3DEBC56086Q33578033-E71EFDBB-AB2E-4D68-AEEA-66199621CE14Q34000153-898F3156-B8DE-44BA-9A93-197A9F17386FQ34001012-6CB1925E-F743-41E0-A77C-EF60B34CAA57Q34002698-BC9046B2-0F28-4737-AD30-43333400779BQ35388488-B8DC1803-70B6-4F24-A449-43F2F1277A6DQ35485187-19A731FA-2B48-4912-9A88-96E18BE63887Q35687523-24E75522-A383-4ACD-A9DD-309B19CBA0A3Q36045133-6C263A5D-0A38-4560-82B1-8FDF8BB3993DQ36551627-B9C590CF-544C-451C-A270-4D6A8EBCBF84Q36915108-0223C75B-A8A5-44EB-851A-F11894AAE43FQ37375983-2D67DF69-6D69-47B0-8730-65938D98A9EBQ37483766-1DA0CA8A-69F3-4F17-8B7C-DFA790222D6EQ37544964-EA8A42AC-3350-4841-B457-D0984D096738Q37710341-B11F7D12-3E0F-4D22-8D02-AB5B4673AE27Q39830996-0E83D408-3987-4EC5-8349-5F251D621564Q41417451-0082AE78-07CC-43B8-B332-1C8FF8DF2F2BQ41986831-4A6E7AA7-FE64-4FCC-A280-B5F7A92E30C5
P2860
Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels.
description
1993 nî lūn-bûn
@nan
1993 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Safety, immunogenicity, and ex ...... and low socioeconomic levels.
@ast
Safety, immunogenicity, and ex ...... and low socioeconomic levels.
@en
type
label
Safety, immunogenicity, and ex ...... and low socioeconomic levels.
@ast
Safety, immunogenicity, and ex ...... and low socioeconomic levels.
@en
prefLabel
Safety, immunogenicity, and ex ...... and low socioeconomic levels.
@ast
Safety, immunogenicity, and ex ...... and low socioeconomic levels.
@en
P2093
P2860
P1476
Safety, immunogenicity, and ex ...... and low socioeconomic levels.
@en
P2093
C F Lanata
G Losonsky
S S Wasserman
P2860
P304
P407
P577
1993-09-01T00:00:00Z